Skip to main content
All lobbying filings

CENTER FOR INDIVIDUAL FREEDOM

Lobbying for CENTER FOR INDIVIDUAL FREEDOM

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · Virginia · House · Senate · $20,000.00 expenses · posted Jul 16, 2026

Official filing document

 Bills named in this filing 11
  • S 3903
    Railway Safety Act of 2026
  • HR 7748
    Railway Safety Act of 2026
  • HR 8293
    Abolish the CMMI Act
  • HR 8413
    SECURE Data Act
  • HR 7742
    Keep It Moving Act
  • S 4198
    Main Street Depositor Protection Act
  • HR 8087
    Main Street Depositor Protection Act
  • HR 1515
    GOOD Act
  • HR 6329
    Information Quality Assurance Act of 2025
  • HJRES 157
    Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the En…
  • S 2658
    Medication Affordability and Patent Integrity Act
 Lobbying activity 11
Trade (domestic/foreign)

Correspondence in general support of Section 301 investigations into the acts, policies and practices of foreign economies that burden U.S. commerce, and address discrimination against U.S. technology companies and their users, digital services taxes and related unfair trade practices; research relating thereto.

Railroads

S. 3903/H.R. 7748 - Railway Safety Act Correspondence with the President of the United States, United States Senate and United States House of Representatives in opposition to the Railway Safety Act (RSA); research relating thereto.

Medicare/Medicaid

H.R. 8293 - Abolish the Center for Medicare and Medicaid Innovation (CMMI) Act Correspondence with United States House of Representatives in support H.R. 8293; research relating thereto.

Health Issues

Correspondence with United States House of Representatives in general opposition to proposals calling for codification a federal Most Favored Nation (MFN) pharmaceutical pricing policy into law; research relating thereto. ------------------- Correspondence with United States Senate and United States House of Representatives in general opposition to any effort to quash direct-to-consumer (DOC) advertising of prescription drugs; research relating thereto.

Consumer Issues/Safety/Products

H.R. 8413 - SECURE Data Act Correspondence with United States House of Representatives in support of the SECURE Data Act (H.R. 8413) to establish a national privacy and data security framework; research relating thereto.

Communications/Broadcasting/Radio/TV

Correspondence with the United States Senate in general opposition to any effort related to government-mandated adoption of ATSC 3.0 television broadcast standards; research relating thereto. -------------------- H.R. 7742 - Keep It Moving Act Correspondence with United States Senate and United States House of Representatives in support of the Keep It Moving Act (H.R. 7742) to establish a 180-day limit for the Federal Communications Commission (FCC) to act on license transfer or assignment applications and other transactions under its jurisdiction; research relating thereto.

Banking

Correspondence with the United States Office of the Comptroller of the Currency in general support of efforts to preempt the Illinois Interchange Fee Prohibition Act under federal law and the Constitutions Supremacy Clause and Commerce Clause; research relating thereto. -------------------- S. 4198/H.R. 8087 - Main Street Depositor Protection Act Correspondence with United States Senate and United States House of Representatives in opposition to the Main Street Depositor Protection Act (S. 4198, H.R. 8087), which would give the FDIC the authority to permanently increase federal deposit insurance coverage for certain noninterest-bearing transaction accounts; research relating thereto.

Government Issues

H.R. 1515 - Guidance Out of Darkness (GOOD) Act H.R. 6329 - Information Quality Assurance (IQAA) Act Correspondence with United States Senate and United States House of Representatives in support of the Guidance Out of Darkness (GOOD) Act (H.R. 1515) and the Information Quality Assurance Act (IQAA) (H.R. 6329) to increase regulatory transparency, including new rules, guidance documents, interpretive rules, policy statements, memoranda, FAQs, circulars and other sub-regulatory materials; research relating thereto.

Torts

Correspondence with United States Senate and United States House of Representatives generally urging action to close tax loopholes that benefit third-party litigation financiers, including via capital gains treatment; research relating thereto.

Energy/Nuclear

H.J.Res 157 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "Renewable Fuel Standard (RFS) Program: Standards for 2026 and 2027, Partial Waiver of 2025 Cellulosic Biofuel Volume Requirement, and Other Changes" Correspondence with United States Senate and United States House of Representatives in support of Congressional Review Act resolution disapproving of the final Renewable Fuel Standard (RFS) volume mandates for 2026 and 2027 by the Environmental Protection Agency (EPA); research relating thereto. ---------------------- Correspondence with the United States Small Business Administration in general support of revising elements of the Environmental Protection Agencys Greenhouse Gas Reporting Program, especially Subpart W; research relating thereto.

Copyright/Patent/Trademark

S.2658 - Medication Affordability and Patent Integrity Act Correspondence with United States Senate in opposition to the Medication Affordability and Patent Integrity Act (S.2658); research relating thereto.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem